TY - JOUR
T1 - Use of ceftaroline in hospitalized patients with and without covid-19
T2 - A descriptive cross-sectional study
AU - Giacobbe, Daniele Roberto
AU - Russo, Chiara
AU - Martini, Veronica
AU - Dettori, Silvia
AU - Briano, Federica
AU - Mirabella, Michele
AU - Portunato, Federica
AU - Dentone, Chiara
AU - Mora, Sara
AU - Giacomini, Mauro
AU - Berruti, Marco
AU - Bassetti, Matteo
N1 - Funding Information:
Conflicts of Interest: Outside the submitted work, D.R.G. reports honoraria from Stepstone Pharma GmbH and unconditional grants from MSD Italia and Correvio Italia. Outside the submitted work, M.B. (Matteo Bassetti) has received funding for scientific advisory boards, travel and speaker honoraria from Angelini, Astellas, AstraZeneca, Basilea, Bayer, BioMérieux, Cidara, Correvio, Cubist, Menarini, Molteni, MSD, Nabriva, Paratek, Pfizer, Roche, Shionogi, Tetraphase, Thermo Fisher, and The Medicine Company. All the other authors declare no conflicts of interest.
Funding Information:
Funding: This project (291/2018) was funded by a Pfizer ASPIRE grant for investigator-initiated research (2018 ASPIRE Awards Program in Anti-Infectives—Project number WI242147). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/7
Y1 - 2021/7
N2 - A single-center cross-sectional study was conducted to describe the use of ceftaroline in a large teaching hospital in Northern Italy, during a period also including the first months of the coronavirus disease 2019 (COVID-19) pandemic. The primary objective was to describe the use of ceftaroline in terms of indications and characteristics of patients. A secondary objective was to describe the rate of favorable clinical response in patients with bloodstream infections (BSI) due to methicillin-resistant Staphylococcus aureus (MRSA-BSI) receiving ceftaroline. Overall, 200 patients were included in the study. Most of them had COVID-19 (83%, 165/200) and were hospitalized in medical wards (78%, 155/200). Included patients with COVID-19 pneumonia were given empirical ceftaroline in the suspicion of bacterial co-infection or superinfection. Among patients with MRSA-BSI, ceftaroline was used as a first-line therapy and salvage therapy in 25% (3/12) and 75% (9/12) of cases, respectively, and as a monotherapy or in combination with daptomycin in 58% (7/12) and 42% (5/12) of patients, respectively. A favorable response was registered in 67% (8/12) of patients. Improving etiological diagnosis of bacterial infections is essential to optimize the use of ceftaroline in COVID-19 patients. The use of ceftaroline for MRSA-BSI, either as a monotherapy or in combination with other anti-MRSA agents, showed promising rates of favorable response.
AB - A single-center cross-sectional study was conducted to describe the use of ceftaroline in a large teaching hospital in Northern Italy, during a period also including the first months of the coronavirus disease 2019 (COVID-19) pandemic. The primary objective was to describe the use of ceftaroline in terms of indications and characteristics of patients. A secondary objective was to describe the rate of favorable clinical response in patients with bloodstream infections (BSI) due to methicillin-resistant Staphylococcus aureus (MRSA-BSI) receiving ceftaroline. Overall, 200 patients were included in the study. Most of them had COVID-19 (83%, 165/200) and were hospitalized in medical wards (78%, 155/200). Included patients with COVID-19 pneumonia were given empirical ceftaroline in the suspicion of bacterial co-infection or superinfection. Among patients with MRSA-BSI, ceftaroline was used as a first-line therapy and salvage therapy in 25% (3/12) and 75% (9/12) of cases, respectively, and as a monotherapy or in combination with daptomycin in 58% (7/12) and 42% (5/12) of patients, respectively. A favorable response was registered in 67% (8/12) of patients. Improving etiological diagnosis of bacterial infections is essential to optimize the use of ceftaroline in COVID-19 patients. The use of ceftaroline for MRSA-BSI, either as a monotherapy or in combination with other anti-MRSA agents, showed promising rates of favorable response.
KW - Ceftaroline
KW - COVID-19
KW - MRSA
KW - Staphylococcus aureus
UR - http://www.scopus.com/inward/record.url?scp=85109153109&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85109153109&partnerID=8YFLogxK
U2 - 10.3390/antibiotics10070763
DO - 10.3390/antibiotics10070763
M3 - Article
AN - SCOPUS:85109153109
SN - 2079-6382
VL - 10
JO - Antibiotics
JF - Antibiotics
IS - 7
M1 - 763
ER -